Details
Category: Volume 07 Issue 03 March 2019
Hits: 1159

Title: Extra pyramidal symptoms between patients consuming typical and atypical anti-psychotics-in tertiary care centre, in eastern India

Authors: Mihir Ranjan Nayak, Manaswini Dash, Debjani Das, Debasish Biswal

 DOI: https://dx.doi.org/10.18535/jmscr/v7i3.82

Abstract

Introduction: The introduction of second-generation antipsychotics, with atypical mechanism of action, especially lower dopamine receptors affinity, has met with great expectations among clinicians regarding their potentially lower propensity to cause extrapyramidal syndrome. Numerous studies have examined the incidence and severity of extrapyramidal syndrome with first- and second-generation antipsychotics.

Material and Methods: 100 patients with any psychotic symptoms were taken up in this study. Extra pyramidal symptoms were assessed after taking antipsychotics by applying by –extra-pyramidal side effects scale, Barnes akathisia scale and abnormal involuntary moments scale at the interval of 1 week,2 months, 3 months, 6 months, 9 months & 1 year.

Results: At the end of 1 year treatment based on Extrapyramidal side effects scale that of Bradykinesia –rigidity, observed rigidity, gait and posture, reported tremor, observed tremor, BARS,AIMS scores are more in patients receiving typical antipsychotics than atypical antipsychotics

Interpretation and Conclusion: EPS are more in patients receiving typical antipsychotics than atypical antipsychotics.

Keywords: Anti-Psychotics,extra pyramidal symptoms, comparison.

References

  1. Aguglia E.et al : Insight in persons with schizophrenia : effects of switching from conventional neuropeptics to atypical Prog Neuropsycho-pharmacol Biond psychiatry.2002 Dec ; 26(7-8):1229-33.
  2. Barene’s TRE-A Rating scale for drug induced akathisia. Dr. J Psychiatry 1989;1548-672-676.
  3. Bobes J et al : Safety and effectiveness of obanzapinevs conventional antipsychotics in the acute treatment of first –episode schizophrenia in patients. Progneuro-psychopharmacol Biol psychiatry, 2003 MAY;27(3):473-81.
  4. Den Boer JA et al : Atypical neuraleptics in acute schizophrenia : a double- blind comparative study of remoxipride and haloperidol. Psychopharmacal Bull.1990; 26(1):99-107.
  5. Joseph Peuskens& Marc De Hert : “Good Medical Practice Antipsychotics, Effects and Side-effects”.
  6. Klieser E et al : Randomized, double-blind, controlled trial of risperidonevs olanzapine in patients with chronic schizophrenia. J Clin psychoparmacol 1995 Feb; 15(1 suppll) : 45s-51s.
  7. Lewis R. Typical and atypical antipsychotics’s in abode scent schizophrenia; efficacy, tolerability and differential sensitivity to extra-pyramidal symptoms. Can J 1983 Aug. 43 (6) 596-604 related Articles ,Linbs.
  8. Franz M. et al : conventional versus atypical narcoleptics : subjective quality of life in schizophrenic patients Br. J. Psychiatry.1997, May;176:422-5
  9. Gerlach J. New Antipsychotics : classification, efficacy and adverse effects. Schizophr Bull. 1991;17(2):289-309.Claus A Risperidone versus haloperidol in the treatment of chronic  schizophrenic in patients  : a multicentre  double-blind  comparative study. Ata psychiatry scand.1992 Apr;85(4):295-305
  10. Glazer WM. Extra-pyramidal side effects, tardive dyskinesia, and the concept of atypicality. J clinPsychiatry 2000; 61 suppl 3 : 16-21 related articles,links
  11. Krauszy M, et al : “Neurolepitic induced extra-pyramidal symptoms are accompanied by cognitive dysfunction in schizophrenia” ; 1999
  12. Lane Rd et al : “Assessment of Tardive Dyskinesia using the Abnormal involuntary Movement Scales” ; J Nerv. Ment Dis .1985,173: 353-7
  13. Crossley NA, Constante M, McGuire P, Power P (2010) Efficacy of atypical v. typical antipsychotics in the treatment of early psychosis: meta-analysis. Br J Psychiatry 196: 434–439.
  14. Inada Y, Yagi G, Miura S. Extrapyramidal symptom pro- files in Japanese patients with schizophrenia treated with olanzapine or haloperidol. Schizophr. Res. 2002; 57: 227– 238.
  15. Voruganti L, Cortese L, Owyeumi K et al. Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study. Schizophr. Res. 2002; 57: 201–208.
  16. Aoba A. Typical and atypical anti-psychotic drugs used for the treatment of schizophrenia. Seishin Shinkeigaku Zasshi 2001; 103: 523–531
  17. Naber D. Subjective experiences of schizophrenic patients treated with antipsychotic medication. Int. Clin. Psychopharmacol. 1998; 13 (Suppl. 1): S41–S45
  18. Tempier R &Pawliuk N. Influence of novel and conventional antipsychotic medication on subjective quality of life. J. Psychiatry Neurosci. 2001; 26: 131–136.
  19. RitsnerM, Ponizovsky A, Endicott J et al. The impact of side-effects of antipsychotic agents on life satisfaction of schizophrenia patients: a naturalistic study. Eur. Neuropsychopharmacol. 2002; 12: 31–38.

Corresponding Author

Manaswini Dash

2nd yr PG Student in Psychiatry, MHI, COE, SCB, MCH, Cuttack, Odisha, India